Search Results - "Elisabetta Degasperi"

Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies by Degasperi, Elisabetta, Anolli, Maria Paola, Lampertico, Pietro

“…Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent…”
Get full text

Direct-acting antivirals: the endgame for hepatitis C? by D’Ambrosio, Roberta, Degasperi, Elisabetta, Colombo, Massimo, Aghemo, Alessio

“…•DAAs for HCV treatment include protease (NS3/4A) inhibitors, RNA-dependent polymerase (NS5B) inhibitors and NS5A inhibitors.•The combination of DAA owning to…”
Get full text

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis by Sapena, Victor, Enea, Marco, Torres, Ferran, Celsa, Ciro, Rios, Jose, Rizzo, Giacomo Emanuele Maria, Nahon, Pierre, Mariño, Zoe, Tateishi, Ryosuke, Minami, Tatsuya, Sangiovanni, Angelo, Forns, Xavier, Toyoda, Hidenori, Brillanti, Stefano, Conti, Fabio, Degasperi, Elisabetta, Yu, Ming-Lung, Tsai, Pei-Chien, Jean, Kevin, El Kassas, Mohamed, Shousha, Hend Ibrahim, Omar, Ashraf, Zavaglia, Claudio, Nagata, Hiroko, Nakagawa, Mina, Asahina, Yasuhiro, Singal, Amit G, Murphy, Caitlin, Kohla, Mohamed, Masetti, Chiara, Dufour, Jean-François, Merchante, Nicolas, Cavalletto, Luisa, Chemello, Liliana Lc, Pol, Stanislas, Crespo, Javier, Calleja, Jose Luis, Villani, Rosanna, Serviddio, Gaetano, Zanetto, Alberto, Shalaby, Sarah, Russo, Francesco Paolo, Bielen, Rob, Trevisani, Franco, Cammà, Calogero, Bruix, Jordi, Cabibbo, Giuseppe, Reig, Maria

“…The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This…”
Get more information

Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy by Tosetti, Giulia, Degasperi, Elisabetta, Farina, Elisa, D'Ambrosio, Roberta, Soffredini, Roberta, Borghi, Marta, La Mura, Vincenzo, Primignani, Massimo, Lampertico, Pietro

“…Nonselective β-blockers improve decompensation-free survival in viremic hepatitis C virus compensated cirrhotic patients with clinically significant portal…”
Get full text

The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD) by D'Ambrosio, Roberta, Campi, Irene, Maggioni, Marco, Perbellini, Riccardo, Giammona, Enza, Stucchi, Roberta, Borghi, Marta, Degasperi, Elisabetta, De Silvestri, Annalisa, Persani, Luca, Fugazzola, Laura, Lampertico, Pietro

“…Data on the role of hypothyroidism in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis are conflicting, although selective…”
Get full text

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients by Wong, Yu Jun, Zhaojin, Chen, Tosetti, Guilia, Degasperi, Elisabetta, Sharma, Sanchit, Agarwal, Samagra, Chuan, Liu, Huak, Chan Yiong, Jia, Li, Xiaolong, Qi, Saraya, Anoop, Primignani, Massimo

“…The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease…”
Get full text

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon by D'Ambrosio, Roberta, Degasperi, Elisabetta, Aghemo, Alessio, Fraquelli, Mirella, Lampertico, Pietro, Rumi, Maria Grazia, Facchetti, Floriana, Grassi, Eleonora, Casazza, Giovanni, Rosenberg, William, Bedossa, Pierre, Colombo, Massimo

“…Liver biopsy (LB) has lost popularity to stage liver fibrosis in the era of highly effective anti-hepatitis C virus (HCV) therapy, yet diagnosis of persistent…”
Get full text

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure by Graf, Christiana, D’Ambrosio, Roberta, Degasperi, Elisabetta, Paolucci, Stefania, Llaneras, Jordi, Vermehren, Johannes, Dultz, Georg, Peiffer, Kai-Henrik, Finkelmeier, Fabian, Herrmann, Eva, Zeuzem, Stefan, Buti, Maria, Lampertico, Pietro, Dietz, Julia, Sarrazin, Christoph

“…Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV…”
Get full text

Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations by Shekhtman, Louis, Cotler, Scott J., Degasperi, Elisabetta, Anolli, Maria Paola, Uceda Renteria, Sara Colonia, Sambarino, Dana, Borghi, Marta, Perbellini, Riccardo, Facchetti, Floriana, Ceriotti, Ferruccio, Lampertico, Pietro, Dahari, Harel

“…Bulevirtide (BLV) was approved for the treatment of compensated chronic hepatitis D virus (HDV) infection in Europe in 2020. However, research into the effects…”
Get full text

Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy by Tan-Garcia, Alfonso, Lai, Fritz, Yeong, Joe Poh Sheng, Irac, Sergio E., Ng, Pei Y., Msallam, Rasha, Lim, Jeffrey Chun Tatt, Wai, Lu-En, Tham, Christine Y.L., Choo, Su P., Lim, Tony, Young, Dan Y., D'Ambrosio, Roberta, Degasperi, Elisabetta, Perbellini, Riccardo, Newell, Evan, Le Bert, Nina, Ginhoux, Florent, Bertoletti, Antonio, Chen, Qingfeng, Dutertre, Charles-Antoine

“…Chronic liver inflammation leads to fibrosis and cirrhosis and is associated with an accumulation of intrahepatic TNFα-secreting CD206+ macrophages, which may…”
Get full text

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir by Aghemo, Alessio, Grassi, Eleonora, Rumi, Maria Grazia, D'Ambrosio, Roberta, Galmozzi, Enrico, Degasperi, Elisabetta, Castaldi, Davide, Soffredini, Roberta, Colombo, Massimo

“…Severe anemia is a common side effect of Pegylated Interferon + Ribavirin (PR) and Telaprevir (TVR) in hepatitis C virus (HCV) genotype 1 patients with…”
Get full text

PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history by Degasperi, Elisabetta, Viganò, Mauro, Aghemo, Alessio, Lampertico, Pietro, Colombo, Massimo

“…Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect…”
Get more information

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study by Valenti, Luca, Pelusi, Serena, Aghemo, Alessio, Gritti, Sara, Pasulo, Luisa, Bianco, Cristiana, Iegri, Claudia, Cologni, Giuliana, Degasperi, Elisabetta, D’Ambrosio, Roberta, Poggio, Paolo, Soria, Alessandro, Puoti, Massimo, Carderi, Isabella, Pigozzi, Marie Graciella, Carriero, Canio, Spinetti, Angiola, Zuccaro, Valentina, Memoli, Massimo, Giorgini, Alessia, Viganò, Mauro, Rumi, Maria Grazia, Re, Tiziana, Spinelli, Ombretta, Colombo, Maria Chiara, Quirino, Tiziana, Menzaghi, Barbara, Lorini, Gianpaolo, Pan, Angelo, D’Arminio Monforte, Antonella, Buscarini, Elisabetta, Autolitano, Aldo, Bonfanti, Paolo, Terreni, Natalia, Aimo, Gianpiero, Mendeni, Monia, Prati, Daniele, Lampertico, Pietro, Colombo, Massimo, Fagiuoli, Stefano

“…The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real‐life cohort…”
Get full text

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients by Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani

“…Background/Aims: The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced…”
Get full text

Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review by Degasperi, Elisabetta, Anolli, Maria Paola, Lampertico, Pietro

“…Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until recently, the only therapeutic approach has been the off‐label use of…”
Get full text

HDV RNA and liver disease progression: What do we know? by Stockdale, Alexander J, Degasperi, Elisabetta

Get full text

Bulevirtide for patients with compensated chronic hepatitis delta: A review by Degasperi, Elisabetta, Anolli, Maria P., Lampertico, Pietro

“…Chronic hepatitis delta (CHD) affects approximately 10–20 million people worldwide and represents the most severe form of chronic viral hepatitis, as it is…”
Get full text

Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: Is it really needed in patients with cured HCV or suppressed HBV? by Tosetti, Giulia, Degasperi, Elisabetta, Farina, Elisa, Primignani, Massimo, Lampertico, Pietro

Get full text

Suboptimal accuracy of GES score to stratify post‐SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype by Bergna, Irene, Degasperi, Elisabetta, D'Ambrosio, Roberta

Get full text

Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR by D’Ambrosio, Roberta, Degasperi, Elisabetta, Anolli, Maria Paola, Fanetti, Ilaria, Borghi, Marta, Soffredini, Roberta, Iavarone, Massimo, Tosetti, Giulia, Perbellini, Riccardo, Sangiovanni, Angelo, Sypsa, Vana, Lampertico, Pietro

“…As the long-term benefits of a sustained virological response (SVR) in HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain…”
Get full text